1. Home
  2. FINS vs AKBA Comparison

FINS vs AKBA Comparison

Compare FINS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

FINS

Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

HOLD

Current Price

$12.70

Market Cap

433.2M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.93

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINS
AKBA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.2M
375.0M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
FINS
AKBA
Price
$12.70
$0.93
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
33.7K
5.5M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.38
$0.88
52 Week High
$13.55
$4.08

Technical Indicators

Market Signals
Indicator
FINS
AKBA
Relative Strength Index (RSI) 45.17 33.94
Support Level $12.47 $0.88
Resistance Level $13.18 $1.56
Average True Range (ATR) 0.18 0.07
MACD 0.00 0.00
Stochastic Oscillator 42.65 27.29

Price Performance

Historical Comparison
FINS
AKBA

About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

Angel Oak Financial Strats Income Term Trust is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: